Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Search by expertise, name or affiliation
The safety of zoledronic acid
Allan Lipton
Department of Medicine
Division of Hematology and Oncology
Penn State Cancer Institute
Research output
:
Contribution to journal
›
Review article
›
peer-review
31
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The safety of zoledronic acid'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Zoledronic Acid
100%
Multiple Myeloma
25%
Solid Tumors
25%
Safety Profile
25%
Patient Demographics
25%
Clinical Experience
25%
Renal Disease
25%
Ocular Complications
25%
Randomized Phase III Trial
25%
Hypercalcemia of Malignancy
25%
Vitamin D Supplementation
25%
Dose Reduction
25%
Flu-like
25%
Malignant Bone Disease
25%
Osteonecrosis of the Jaw
25%
Medicine and Dentistry
Zoledronic Acid
100%
Side Effect
25%
Solid Malignant Neoplasm
25%
Multiple Myeloma
25%
Supplementation
25%
Patient Population
25%
Isotopes of Calcium
25%
Dental Procedure
25%
Cancer
25%
Bone Disease
25%
Vitamin D
25%
Hypercalcaemia
25%
Flu Like Syndrome
25%
Disorders of Calcium Metabolism
25%
Drug Dose Reduction
25%
Pharmacology, Toxicology and Pharmaceutical Science
Zoledronic Acid
100%
Solid Malignant Neoplasm
25%
Multiple Myeloma
25%
Side Effect
25%
Bone Disease
25%
Vitamin D
25%
Hypercalcaemia
25%
Flu Like Syndrome
25%
Electrolyte Disturbance
25%
Jaw Osteonecrosis
25%